Semaglutide + Glycine Injection

(Ship Cold)

Available Dosage Strengths

2.5 mg / 7.5 mg/mL

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Semaglutide^1-4

Semaglutide, a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA), is an incretin mimetic. Incretins are released from the gastrointestinal tract into the systemic circulation to improve glycemic control. The drug is used for the following indications:

For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise

For the reduction of risk of major adverse cardiovascular events, including reduction of cardiovascular mortality, non-fatal myocardial infarction, or non-fatal stroke, in individuals with established cardiovascular disease and type 2 diabetes mellitus, chronic kidney disease and type 2 diabetes mellitus, or established cardiovascular disease and obesity or who are overweight

For the treatment of obesity and for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity

For the treatment of metabolic dysfunction-associated steatotic liver disease† (MASLD) or metabolic dysfunction-associated steatohepatitis† (MASH) in people with type 2 diabetes mellitus

Glycine

Glycine is an amino acid that can be synthesized in the body. It is an amino acid that is found in the structure of proteins in the body including collagen, creatine, and purine nucleotides. In the plasma, it accounts for 11.5% of the total amino acids. It has been studied in marathon runners for its anti-inflammatory and immunomodulatory activity and its ability to benefit physical performance and muscle growth. It also has been shown to have a role in the prevention of lung injuries, gastric ulcers and during hemorrhagic and endotoxic shock.

Mechanism of Action

Mechanism of Action^1-4

Semaglutide

Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.

Glycine

Glycine exerts its anti-inflammatory effects by inhibiting cytokine synthesis, reducing serum transaminase levels and works on decreasing calcium levels inside cells. The cytokines that glycine inhibits are TNF-a, interleukin-6, interleukin-1b. It also increases the levels of anti-inflammatory cytokines including interleukin-10 found in macrophages and leucocytes.

Adverse Reactions

Adverse Reactions^1-3

Semaglutide and Glycine

Common

Most adverse reactions are gastrointestinal in nature and dose-dependent:

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite, abdominal pain
Headache, dizziness, and injection site reactions

Contraindications & Precautions

Contraindications & Precautions^1-3

Contraindications:

Hypersensitivity to semaglutide or glycine or its components

In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2

In patients who are pregnant

Precautions:

In patients with a history of pancreatitis and gall bladder disease

In patients with renal and hepatic impairment

Storage

Storage^1-3

Refrigerate at 2–8°C (36–46°F) before and during use. Do not freeze. Protect from light and excessive heat.

References

Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
Ramos-Jiménez A, Hernández-Torres RP, Hernández-Ontiveros DA, Ortiz-Ortiz M, López-Fregoso RJ, Martínez-Sanz JM, Rodríguez-Uribe G, Hernández-Lepe MA. An Update of the Promise of Glycine Supplementation for Enhancing Physical Performance and Recovery. Sports (Basel). 2024 Sep 25;12(10):265.
Aguayo-Cerón KA, Sánchez-Muñoz F, Gutierrez-Rojas RA, Acevedo-Villavicencio LN, Flores-Zarate AV, Huang F, Giacoman-Martinez A, Villafaña S, Romero-Nava R. Glycine: The Smallest Anti-Inflammatory Micronutrient. Int J Mol Sci. 2023 Jul 8;24(14):11236.
Razak MA, Begum PS, Viswanath B, Rajagopal S. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxid Med Cell Longev. 2017;2017:1716701.
Glycine-adverse reaction overview. https://ontosight.ai/glossary/term/glycine-adverse-reaction-overview–67a164126c3593987a56a572. Accessed June 25, 2025

Disclaimer

This sheet is a summary. It may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.